

Cell-penetrating antagomir for acute myocardial infarction (non-clinical study)

RegenInnopharm Inc



CARDIOVASCULAR

Preclinical

| | |
|--------------------------|---|
| Product Type | ASO-antagomir |
| Indication | Acute myocardial infarction |
| Target | miR 145 |
| MoA(Mechanism of Action) | Protect myocardium, inhibit inflammation & fibrosis, promote regeneration |
| Competitiveness | <ul style="list-style-type: none"> Recover heart function (LVEF%) within 4 days after onset to >90% of normal state in pig infarction model. The recovered heart function (>90%) is maintained up to 12 month of FU in pig. Safety(No arrhythmia, no cytokine release storm, no adverse effects at doses 20-40 folds higher than clinical dose) (GLP-DRF) logistics: Lyophilized powder, stable during storage and transport handling Easy use: injected during PCI, no additional process for drug delivery |
| Development Stage | Pre-clinical |
| Route of Administration | Intra-coronary artery (during PCI) |